Treatment of systemic lupus erythematosus with epratuzumab

被引：50

作者：

Traczewski, Pawel ^{[1
]}

Rudnicka, Lidia ^{[1
,2
]}

机构：

[1] Dept Dermatol CSK MSWiA, PL-02507 Warsaw, Poland

[2] Warsaw Med Univ, Div Publ Hlth, Warsaw, Poland

来源：

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY | 2011年 / 71卷 / 02期

关键词：

epratuzumab; monoclonal antibody; rituximab; SLE; systemic lupus erythematosus; HUMANIZED ANTI-CD22 ANTIBODY; NON-HODGKINS-LYMPHOMA; B-CELL DEPLETION; PHASE-I/II TRIAL; MONOCLONAL-ANTIBODY; DOUBLE-BLIND; CLINICAL-TRIAL; CD22; THERAPY; RITUXIMAB;

D O I：

10.1111/j.1365-2125.2010.03767.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Systemic lupus erythematosus is a prototypic autoimmune disease characterized by abnormalities in the activity of B-cells and T-cells. A novel specific treatment for autoimmune diseases is B-cell depletion with monoclonal antibodies. Epratuzumab is a monoclonal antibody that targets CD22 antigen on B-cells. Initial phase II and two terminated early phase III studies suggest that treatment of systemic lupus erythematosus with this immunomodulatory agent is effective, well tolerated and significantly improves the patient's quality of life. In vitro studies and clinical trials with non-Hodgkin lymphoma patients indicate epratuzumab can potentially serve as a complementary drug in combination therapy with another inhibitor of B-cell activity, rituximab, which is a monoclonal anti-CD20 antibody.

引用

收藏

页码：175 / 182

页数：8

相关论文

共 60 条

[1] B-cell Biology and Related Therapies in Systemic Lupus Erythematosus [J].

Ahmed, Sadia ;

Anolik, Jennifer H. .

RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2010, 36 (01) :109-+

[2] LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus -: Results from a randomized, double-blind, placebo-controlled study [J].

Alarcón-Segovia, D ;

Tumlin, JA ;

Furie, RA ;

McKay, JD ;

Cardiel, MH ;

Strand, V ;

Bagin, RG ;

Linnik, MD ;

Hepburn, B .

ARTHRITIS AND RHEUMATISM, 2003, 48 (02) :442-454

[3] Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results [J].

Aletaha, D. ;

Strand, V. ;

Smolen, J. S. ;

Ward, M. M. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (02) :238-243

[4] Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus [J].

Arce, E ;

Jackson, DG ;

Gill, MA ;

Bennett, LB ;

Banchereau, J ;

Pascual, V .

JOURNAL OF IMMUNOLOGY, 2001, 167 (04) :2361-2369

[5] Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future the EULAR recommendations for the management of SLE and the use of end-points in clinical trials [J].

Bertsias, G. ;

Gordon, C. ;

Boumpas, D. T. .

LUPUS, 2008, 17 (05) :437-442

[6] A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis [J].

Boumpas, DT ;

Furie, R ;

Manzi, S ;

Illei, GG ;

Wallace, DJ ;

Balow, JE ;

Vaishnaw, A .

ARTHRITIS AND RHEUMATISM, 2003, 48 (03) :719-727

[7]

Carnahan J, 2003, CLIN CANCER RES, V9, p3982S

[8] Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab [J].

Carnahan, Josette ;

Stein, Rhona ;

Qu, Zhengxing ;

Hess, Kristen ;

Cesano, Alessandra ;

Hansen, Hans J. ;

Goldenberg, David M. .

MOLECULAR IMMUNOLOGY, 2007, 44 (06) :1331-1341

[9]

Chan O, 1998, J IMMUNOL, V160, P51

[10] The central and multiple roles of B cells in lupus pathogenesis [J].

Chan, OTM ;

Madaio, MP ;

Shlomchik, MJ .

IMMUNOLOGICAL REVIEWS, 1999, 169 :107-121

← 1 2 3 4 5 6 →